Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Earnings per Share (Diluted) is $0.01 as of Mar. 2026. The stock has 1 warning sign investors should review. Among 159 Medical Diagnostics & Research companies, Invitro International ranks worse than 628930.19% on this metric.
During the past 9 years, Invitro International's highest 3-Year average EPS without NRI Growth Rate was 38.30% per year. The lowest was -73.00% per year. And the median was 35.20% per year.
Invitro International (OTCPK:IVRO) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Invitro International Earnings per Share (Diluted) Related Terms
Invitro International Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Invitro International's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International Earnings per Share (Diluted) Chart
IVRO vs IDTA, PRPH, NSTM: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Invitro International's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's PE Ratio distribution charts can be found below:
* The bar in red indicates where Invitro International's PE Ratio falls into.
Invitro International Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Invitro International's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.01 mean?
Invitro International (IVRO) has a Earnings per Share (Diluted) of $0.01 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #999999 out of 159 companies in the Medical Diagnostics & Research industry.
Is Invitro International's Earnings per Share (Diluted) too high?
Invitro International's current Earnings per Share (Diluted) is $0.01. The Medical Diagnostics & Research industry median Earnings per Share (Diluted) is 10.80. Invitro International's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, Invitro International ranks #999999 out of 159 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Invitro International's Earnings per Share (Diluted) compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #999999 out of 159 companies for Earnings per Share (Diluted). This places Invitro International in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.80. Invitro International's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.80, based on 159 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Earnings per Share (Diluted) of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Earnings per Share (Diluted) is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Earnings per Share (Diluted) is $0.01 and 99.9% below the Medical Diagnostics & Research industry median of 10.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Invitro International (IVRO), the current Earnings per Share (Diluted) is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
